Molecular Biomarkers Predict Pathological Complete Response of Neoadjuvant Chemotherapy in Breast Cancer Patients: Review

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2021 Nov 13

PMID 34771640

Citations 12

Authors

Ana Julia Aguiar de Freitas

Rhafaela Lima Causin

Muriele Bertagna Varuzza

Cassio Murilo Trovo Hidalgo Filho

Vinicius Duval da Silva

Cristiano de Padua Souza

Marcia Maria Chiquitelli Marques

Affiliations

Soon will be listed here.

Abstract

Neoadjuvant chemotherapy (NAC) is often used to treat locally advanced disease for tumor downstaging, thus improving the chances of breast-conserving surgery. From the NAC response, it is possible to obtain prognostic information as patients may reach a pathological complete response (pCR). Those who do might have significant advantages in terms of survival rates. Breast cancer (BC) is a heterogeneous disease that requires personalized treatment strategies. The development of targeted therapies depends on identifying biomarkers that can be used to assess treatment efficacy as well as the discovery of new and more accurate therapeutic agents. With the development of new "OMICS" technologies, i.e., genomics, transcriptomics, and proteomics, among others, the discovery of new biomarkers is increasingly being used in the context of clinical practice, bringing us closer to personalized management of BC treatment. The aim of this review is to compile the main biomarkers that predict pCR in BC after NAC.

Citing Articles

Advances in analytical approaches for background parenchymal enhancement in predicting breast tumor response to neoadjuvant chemotherapy: A systematic review.

Thomas J, Malla L, Shibwabo B PLoS One. 2025; 20(3):e0317240.

PMID: 40053513 PMC: 11888135. DOI: 10.1371/journal.pone.0317240.

Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy.

Pernas S, Sanfeliu E, Villacampa G, Salvador J, Perello A, Gonzalez X NPJ Breast Cancer. 2024; 10(1):101.

PMID: 39592624 PMC: 11599376. DOI: 10.1038/s41523-024-00710-x.

The Predictive Role of Radiomics in Breast Cancer Patients Imaged by [F]FDG PET: Preliminary Results from a Prospective Cohort.

Gelardi F, Cavinato L, De Sanctis R, Ninatti G, Tiberio P, Rodari M Diagnostics (Basel). 2024; 14(20).

PMID: 39451637 PMC: 11506751. DOI: 10.3390/diagnostics14202312.

18F-FDG PET/CT for early prediction of pathological complete response in breast cancer neoadjuvant therapy: a retrospective analysis.

Wu Y, Li Y, Chen B, Zhang Y, Xing W, Guo B Oncologist. 2024; 29(12):e1646-e1655.

PMID: 39045652 PMC: 11630790. DOI: 10.1093/oncolo/oyae185.

Cancer-associated fibroblasts mediate resistance to neoadjuvant therapy in breast cancer.

Xia Z, Vermeulen S, Suwal U, Rappu P, Heino J, De Vuyst F Clin Transl Med. 2024; 14(7):e1779.

PMID: 39032166 PMC: 11260170. DOI: 10.1002/ctm2.1779.

References

Muller V, Gade S, Steinbach B, Loibl S, von Minckwitz G, Untch M . Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial. Breast Cancer Res Treat. 2014; 147(1):61-8. DOI: 10.1007/s10549-014-3079-3. View

Shamai G, Binenbaum Y, Slossberg R, Duek I, Gil Z, Kimmel R . Artificial Intelligence Algorithms to Assess Hormonal Status From Tissue Microarrays in Patients With Breast Cancer. JAMA Netw Open. 2019; 2(7):e197700. PMC: 6661721. DOI: 10.1001/jamanetworkopen.2019.7700. View

Openshaw M, Page K, Fernandez-Garcia D, Guttery D, Shaw J . The role of ctDNA detection and the potential of the liquid biopsy for breast cancer monitoring. Expert Rev Mol Diagn. 2016; 16(7):751-5. DOI: 10.1080/14737159.2016.1184974. View

Connolly R, Fackler M, Zhang Z, Zhou X, Goetz M, Boughey J . Tumor and serum DNA methylation in women receiving preoperative chemotherapy with or without vorinostat in TBCRC008. Breast Cancer Res Treat. 2017; 167(1):107-116. PMC: 5793219. DOI: 10.1007/s10549-017-4503-2. View

Guo S, Loibl S, von Minckwitz G, Darb-Esfahani S, Lederer B, Denkert C . PIK3CA H1047R Mutation Associated with a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated with Anthracycline-Taxane-Based Neoadjuvant Chemotherapy. Cancer Res Treat. 2020; 52(3):689-696. PMC: 7373870. DOI: 10.4143/crt.2019.497. View

Fasching P, Loibl S, Hu C, Hart S, Shimelis H, Moore R . BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study. J Clin Oncol. 2018; 36(22):2281-2287. PMC: 6067803. DOI: 10.1200/JCO.2017.77.2285. View

Nielsen T, Parker J, Leung S, Voduc D, Ebbert M, Vickery T . A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res. 2010; 16(21):5222-32. PMC: 2970720. DOI: 10.1158/1078-0432.CCR-10-1282. View

Pease A, Riba L, Gruner R, Tung N, James T . Oncotype DX Recurrence Score as a Predictor of Response to Neoadjuvant Chemotherapy. Ann Surg Oncol. 2018; 26(2):366-371. DOI: 10.1245/s10434-018-07107-8. View

Kong X, Moran M, Zhang N, Haffty B, Yang Q . Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients. Eur J Cancer. 2011; 47(14):2084-90. DOI: 10.1016/j.ejca.2011.06.014. View

10.

Rohanizadegan M . Analysis of circulating tumor DNA in breast cancer as a diagnostic and prognostic biomarker. Cancer Genet. 2018; 228-229:159-168. PMC: 6108954. DOI: 10.1016/j.cancergen.2018.02.002. View

11.

Guan G, Wang Y, Sun Q, Wang L, Xie F, Yan J . Utility of urinary ctDNA to monitoring minimal residual disease in early breast cancer patients. Cancer Biomark. 2020; 28(1):111-119. DOI: 10.3233/CBM-190523. View

12.

Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P . Breast cancer. Nat Rev Dis Primers. 2019; 5(1):66. DOI: 10.1038/s41572-019-0111-2. View

13.

Denkert C, Liedtke C, Tutt A, von Minckwitz G . Molecular alterations in triple-negative breast cancer-the road to new treatment strategies. Lancet. 2016; 389(10087):2430-2442. DOI: 10.1016/S0140-6736(16)32454-0. View

14.

Mueller C, Haymond A, Davis J, Williams A, Espina V . Protein biomarkers for subtyping breast cancer and implications for future research. Expert Rev Proteomics. 2017; 15(2):131-152. PMC: 6104835. DOI: 10.1080/14789450.2018.1421071. View

15.

Goossens N, Nakagawa S, Sun X, Hoshida Y . Cancer biomarker discovery and validation. Transl Cancer Res. 2015; 4(3):256-269. PMC: 4511498. DOI: 10.3978/j.issn.2218-676X.2015.06.04. View

16.

Lokman N, Ween M, Oehler M, Ricciardelli C . The role of annexin A2 in tumorigenesis and cancer progression. Cancer Microenviron. 2011; 4(2):199-208. PMC: 3170418. DOI: 10.1007/s12307-011-0064-9. View

17.

Chuthapisith S, Bean B, Cowley G, Eremin J, Samphao S, Layfield R . Annexins in human breast cancer: Possible predictors of pathological response to neoadjuvant chemotherapy. Eur J Cancer. 2009; 45(7):1274-1281. DOI: 10.1016/j.ejca.2008.12.026. View

18.

Chica-Parrado M, Godoy-Ortiz A, Jimenez B, Ribelles N, Barragan I, Alba E . Resistance to Neoadjuvant Treatment in Breast Cancer: Clinicopathological and Molecular Predictors. Cancers (Basel). 2020; 12(8). PMC: 7463925. DOI: 10.3390/cancers12082012. View

19.

Iorio M, Ferracin M, Liu C, Veronese A, Spizzo R, Sabbioni S . MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005; 65(16):7065-70. DOI: 10.1158/0008-5472.CAN-05-1783. View

20.

Stevic I, Muller V, Weber K, Fasching P, Karn T, Marme F . Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial. BMC Med. 2018; 16(1):179. PMC: 6178264. DOI: 10.1186/s12916-018-1163-y. View